Abbot Financial Management’s Invesco Biotechnology & Genome ETF PBE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $984K | Hold |
12,425
| – | – | 0.41% | 72 |
|
|
2025
Q4 | $1.02M | Hold |
12,425
| – | – | 0.42% | 64 |
|
|
2025
Q3 | $868K | Sell |
12,425
-300
| -2% | -$20.3K | 0.37% | 69 |
|
|
2025
Q2 | $816K | Sell |
12,725
-475
| -4% | -$29.4K | 0.38% | 77 |
|
|
2025
Q1 | $837K | Sell |
13,200
-150
| -1% | -$10.1K | 0.43% | 63 |
|
|
2024
Q4 | $888K | Hold |
13,350
| – | – | 0.44% | 61 |
|
|
2024
Q3 | $932K | Sell |
13,350
-1,150
| -8% | -$79.6K | 0.47% | 57 |
|
|
2024
Q2 | $940K | Hold |
14,500
| – | – | 0.5% | 55 |
|
|
2024
Q1 | $938K | Sell |
14,500
-500
| -3% | -$32.5K | 0.52% | 57 |
|
|
2023
Q4 | $988K | Sell |
15,000
-300
| -2% | -$17.4K | 0.59% | 49 |
|
|
2023
Q3 | $873K | Sell |
15,300
-200
| -1% | -$12.2K | 0.59% | 50 |
|
|
2023
Q2 | $950K | Sell |
15,500
-225
| -1% | -$14K | 0.61% | 49 |
|
|
2023
Q1 | $987K | Hold |
15,725
| – | – | 0.66% | 47 |
|
|
2022
Q4 | $998K | Sell |
15,725
-700
| -4% | -$44.4K | 0.68% | 47 |
|
|
2022
Q3 | $968K | Sell |
16,425
-375
| -2% | -$23.1K | 0.69% | 46 |
|
|
2022
Q2 | $970K | Sell |
16,800
-500
| -3% | -$28.8K | 0.59% | 53 |
|
|
2022
Q1 | $1.07M | Sell |
17,300
-450
| -3% | -$27.5K | 0.52% | 54 |
|
|
2021
Q4 | $1.26M | Sell |
17,750
-1,350
| -7% | -$97.7K | 0.56% | 52 |
|
|
2021
Q3 | $1.43M | Hold |
19,100
| – | – | 0.65% | 46 |
|
|
2021
Q2 | $1.48M | Sell |
19,100
-50
| -0.3% | -$3.71K | 0.65% | 44 |
|
|
2021
Q1 | $1.41M | Sell |
19,150
-50
| -0.3% | -$3.78K | 0.64% | 44 |
|
|
2020
Q4 | $1.35M | Hold |
19,200
| – | – | 0.78% | 43 |
|
|
2020
Q3 | $1.09M | Sell |
19,200
-400
| -2% | -$23.5K | 0.71% | 43 |
|
|
2020
Q2 | $1.14M | Hold |
19,600
| – | – | 0.79% | 41 |
|
|
2020
Q1 | $911K | Sell |
19,600
-2,000
| -9% | -$104K | 0.74% | 43 |
|
|
2019
Q4 | $1.21M | Sell |
21,600
-400
| -2% | -$20.9K | 0.76% | 40 |
|
|
2019
Q3 | $1.04M | Hold |
22,000
| – | – | 0.74% | 41 |
|
|
2019
Q2 | $1.18M | Sell |
22,000
-700
| -3% | -$36.3K | 0.85% | 38 |
|
|
2019
Q1 | $1.25M | Sell |
22,700
-225
| -1% | -$11.9K | 0.97% | 34 |
|
|
2018
Q4 | $1.08M | Hold |
22,925
| – | – | 0.95% | 35 |
|
|
2018
Q3 | $1.36M | Sell |
22,925
-125
| -0.5% | -$7.29K | 1.01% | 34 |
|
|
2018
Q2 | $1.26M | Buy |
23,050
+250
| +1% | +$12.7K | 1% | 35 |
|
|
2018
Q1 | $1.12M | Sell |
22,800
-425
| -2% | -$21.7K | 0.9% | 39 |
|
|
2017
Q4 | $1.09M | Hold |
23,225
| – | – | 0.87% | 44 |
|
|
2017
Q3 | $1.1M | Hold |
23,225
| – | – | 0.92% | 41 |
|
|
2017
Q2 | $1.06M | Buy |
+23,225
| New | +$1M | 0.95% | 38 |
|
Other funds holding PBE
UCFA
GKWIM
YIA
Abbot Financial Management's PBE Position: Q1 2026 in Review
Abbot Financial Management held its Invesco Biotechnology & Genome ETF (PBE) position steady in Q1 2026 at 12,425 shares worth $984K. The position accounts for 0.41% of the portfolio, ranked #72.
Abbot Financial Management first reported a position in PBE in Q2 2017 and has held it in 36 quarters since. The position peaked at $1.48M in Q2 2021. 100 funds tracked by Wall St. Rank hold PBE as of Q1 2026.
- Abbot Financial Management held 12,425 shares of Invesco Biotechnology & Genome ETF worth $984K as of Q1 2026.
- Abbot Financial Management left its Invesco Biotechnology & Genome ETF share count unchanged in Q1 2026.
- Invesco Biotechnology & Genome ETF made up 0.41% of Abbot Financial Management's portfolio in Q1 2026, its #72 holding.
- Abbot Financial Management first reported a position in Invesco Biotechnology & Genome ETF in Q2 2017 and has held it in 36 quarters since.
- Abbot Financial Management's Invesco Biotechnology & Genome ETF position peaked at $1.48M in Q2 2021.
- 100 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q1 2026.
Based on Abbot Financial Management's 13F filing for Q1 2026, filed 13 May 2026.